Extra prostate cancers are being recognized at a later stage

Other prostate cancers will be diagnosed at a later date

(HealthDay) – While men can find solace in a new government report showing that prostate cancer cases have declined overall over the past two decades, the same analysis shows the opposite is true for advanced prostate cancer cases.

According to researchers from the U.S. Centers for Disease Control and Prevention, the number of cancer cases that had spread from the prostate to other parts of the body doubled from 4% to 8% between 2003 and 2017.

“Understanding who has prostate cancer and what the survival numbers are could be important for men who make prostate cancer screening decisions, discuss those decisions with their patients and make recommendations for prostate cancer screening,” said lead researcher Dr. David Siegel. from the CDC Cancer Prevention and Control Division.

Why the Top in Advanced Prostate Cancer? Dr. Anthony D’Amico, professor of radiation oncology at Harvard Medical School in Boston, said the surge was an inevitable consequence of a 2012 recommendation by the U.S. Task Force on Preventive Services against the routine use of prostate cancer screening with the prostate specific antigen (PSA) test.

“We found in 2012 that when the US Task Force on Preventive Services said it would stop PSA screening, it assumed that cancer death rates would rise between 2018 and 2019, and that they would about two to three years earlier would be.” From 2015 to 2016 we would expect distant metastases [cancer that has spread] rise because they were a few years before death, “he explained.

That’s exactly what this report found, noted D’Amico.

“This trend will continue as the recommendation against PSA screening was only reversed [2018]So it will be a couple of years before we see a plateau and eventually a decrease in distant sickness, “he said.” We should have PPE brought back. “

While D’Amico said he believes men should have their PSA levels tested, a conversation between a man and his urologist should be based on whether elevated PSA leads to further diagnosis or treatment.

“We are now diagnosing lower risk cases, but from my point of view bringing the PSA back is not a problem so the low risk cancer patients can discuss whether or not they want treatment and know what the side effects are, and the patients who need to be cured can be cured, “D’Amico said.

Men get more metastatic disease and die, he said. “But because of the reversal of PSA screening, it should go back to where it was, and the only difference is that we’re now smarter about who to treat and who not,” D’Amico said.

The CDC study also looked at racial differences for prostate cancer survival. The researchers found that five-year survival was highest among islanders in the Asia-Pacific region (42%), followed by Hispanics (37%), Alaska Native Americans (32%), black men (32%), and whites Men (29)%).

Understanding prostate cancer rates and survival can help guide treatment and survival care planning, Siegel said.

That study didn’t look at PSA testing trends, but previous studies have found PSA testing being used less frequently, Siegel admitted. “There are many factors, including the decrease in PSA tests, that could contribute to the incidence trends that we reported in this study.”

The results were published in the CDC’s weekly report on morbidity and mortality on October 16.

U.S. incidence of distant prostate cancer 2010-2017

More information:
For more information on PSA testing, see the U.S. Centers for Disease Control and Prevention.

Copyright © 2020 HealthDay. All rights reserved.

Quote: More prostate cancers will be diagnosed at a later date (2020, October 16), which was accessed on October 16, 2020 at https://medicalxpress.com/news/2020-10-prostate-cancers-stage.html

This document is subject to copyright. Except for fair trade for the purpose of private study or research, no part may be reproduced without written permission. The content is provided for informational purposes only.

Comments are closed.